e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel mechanisms in lung injury
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis
G. Gay-Jordi, R. Guillamat-Prats, L. I. Sánchez-López, V. Sirenko, F. Hernandez-Gonzalez, O. Bulbena, A. Xaubet, A. Serrano-Mollar (Barcelona, Mallorca, Spain)
Source:
Annual Congress 2013 –Novel mechanisms in lung injury
Session:
Novel mechanisms in lung injury
Session type:
Thematic Poster Session
Number:
650
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Gay-Jordi, R. Guillamat-Prats, L. I. Sánchez-López, V. Sirenko, F. Hernandez-Gonzalez, O. Bulbena, A. Xaubet, A. Serrano-Mollar (Barcelona, Mallorca, Spain). Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 650
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Transplantation pulmonaire à l’heure de la médecine de précision Lung transplantation in the era of precision medicine
Post-transplant morbidity and mortality in patients with pulmonary fibrosis and telomeric shortening
Treating systemic sclerosis with lung involvement: from observation to stem cell transplantation
Related content which might interest you:
Mesenchymal stem cells and conditioned medium in myofibroblast modulation and collagen production in vascular adventitia and parenchyma of experimental pulmonary fibrosis model
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Alveolar type II cells transplantation in pulmonary fibrosis: Effect on the lung macrophage activation
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Abnormal proliferation and differentiation of c-kit+ lung stem cells in pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Mesenchymal stem cells from adipose tissue reduce bleomycin-induced lung remodeling in late stage
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Role of HGF in the healthy and injured lung
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Year: 2013
Epithelial mesenchymal transition in fibroblastic foci of different fibrosing lung diseases: Repair or remodeling?
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Year: 2013
Modulation of lung CD11c+ dendritic cells by TGF-β in pulmonary fibrosis in mice
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Alveolar epithelial injury and apoptosis
Source: Annual Congress 2007 - Mechanisms in pulmonary fibrosis
Year: 2007
Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept